Aug 4 (Reuters) - Moderna on Tuesday said it has begun its first human trial of an experimental vaccine to protect against ...

Health Canada has authorized Moderna to launch a clinical trial for a vaccine targeting the Bundibugyo form of the Ebola ...

Phase 1 trial will evaluate safety and immune response for a strain of Ebola virus disease with no licensed vaccines ...

The trial, backed by up to $50 million from CEPI, comes as the Congo outbreak surpasses 3,700 confirmed cases and 1,600 deaths ...

Canada has authorized U.S. pharmaceutical giant Moderna to begin clinical trials for a vaccine against the Bundibugyo strain ...

The program is backed by the Coalition for Epidemic Preparedness Innovations, which has committed up to $50 million.

Moderna began a Phase 1 clinical trial of its experimental vaccine mRNA-1469 targeting the Bundibugyo strain of Ebola virus.

Moderna has started first-in-human testing of its mRNA vaccine against Bundibugyo Ebola virus (BDBV), now causing the ...

Moderna has begun a Phase 1 clinical trial of an Ebola vaccine set to target the Bundibugyo strain, which is currently ...

Moderna begins Ebola vaccine trials in Canada for Bundibugyo strain. Phase 1 assesses safety, dosage, and side effects.

Moderna begins human trial for Ebola vaccine with 80 volunteers in Canada to evaluate immune response amid Congo outbreak.

Moderna launched a human trial of an experimental vaccine to protect against Bundibugyo Ebola strain that has killed more ...